FindTrial
Sign In

Mechanism of Anti-Colorectal Cancer by Inhibiting Myb-Mediated CLDN9 Expression and Screening of Targeting Peptides

Mechanism of Anti-Colorectal Cancer by Inhibiting Myb-Mediated CLDN9 Expression and Screening of Targeting Peptides

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117751
Enrollment
Unknown
Registered
2026-01-28
Start date
2025-02-06
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal malignancy

Interventions

Observation group:N/A

Sponsors

Huzhou Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.postoperative pathologically confirmed colorectal cancer patients; 2.Age >= 18 years;

Exclusion criteria

Exclusion criteria: 1.Patients with missing or non-qualifying clinical and pathological data. 2.Patients with a history of or concurrent other malignancies. 3.Patients who had received prior radiotherapy or chemotherapy;

Design outcomes

Primary

MeasureTime frame
Prognostic information;CLDN9 expression level;—

Countries

China

Contacts

Public ContactNeng Lou

Huzhou Center Hospital

louneng0923@163.com+86 572 220 1234

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026